// App-Quantinova.ai

2600 : Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial

Researchers

Presenter

  • Bruce Kirkham

Principal Investigators

  • Proton Rahman

  • Philip Helliwell

  • Alice B Gottlieb

  • Wolf-Henning Boehncke

  • Chenglong Han

Medical Centers

  • Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Rheumatology, St. Clar-s Mercy Hospital, St. John's, NF, Canada

  • LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

  • Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY

  • Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland

  • Janssen Global Services, LLC, Malvern, PA

Locations

  • France

  • United Kingdom

  • Canada

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved